KRM 1648

structure in first source

Also Known As:

3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin; ABI 1648; ABI-1648; ABI1648; KRM-1648; benzoxazinorifamycin; rifalazil; Rifamycin VIII, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-(4-(2-methylpropyl)-1-piperazinyl)-1-oxo-

Networked: 63 relevant articles (23 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - Rifamycins: 416
      - KRM 1648: 63
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Macrocyclic Lactams: 28
    - Rifamycins: 416
      - KRM 1648: 63

Experts

1.	Rothstein, David M: 6 articles (05/2008 - 02/2003)
2.	Campbell, Lee Ann: 3 articles (01/2009 - 06/2006)
3.	Sternlicht, Andrew: 3 articles (10/2007 - 06/2006)
4.	Cynamon, M H: 3 articles (11/2000 - 06/2000)
5.	Batteiger, Byron E: 2 articles (07/2014 - 08/2007)
6.	Suchland, Robert J: 2 articles (05/2008 - 02/2006)
7.	van Duzer, John: 2 articles (10/2007 - 11/2006)
8.	Stamm, Walter E: 2 articles (08/2007 - 02/2006)
9.	Murphy, Christopher K: 2 articles (11/2006 - 06/2006)
10.	Chase, S E: 2 articles (11/2000 - 06/2000)

Related Diseases

1.	Infections 04/01/1993 - "Moreover, the drug allowed almost complete recovery of infected rabbits by week 7. KRM-1648 cleared infections in the lungs, liver, spleen, and kidneys and restored histopathologic features of healthy tissue in the visceral organs. " 11/01/1994 - "[Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols]." 08/01/1998 - "These findings indicate that suppression of inflammatory reactions using MBST is capable to improve the therapeutic efficacy of KRM-1648 in MAC infection. " 05/01/2008 - "The efficacy of rifalazil and other benzoxazinorifamycins was tested in a mouse model of lung infection against Chlamydia pneumoniae. " 12/01/1995 - "Third, anti-IL-10 antibody augmented to some extent the chemotherapeutic efficacy of KRM-1648 against MAC infection, when the drug was given to mice at weeks 2 and 4 after infection. "
2.	Tuberculosis (Tuberculoses) 02/01/2002 - "tuberculosis, were resistant to KRM-1648. " 07/01/2001 - "Rifalazil has potent bactericidal activity against Mycobacterium tuberculosis in vitro and in animal models of tuberculosis (TB). " 06/01/2000 - "Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice." 01/01/1997 - "These results suggests that KRM-1648 should further be explored in the treatment of tuberculosis patients." 04/01/1996 - "KRM-1648 showed an excellent chemotherapeutic activity, as compared to RFB and RIF, against drug-susceptible tuberculosis. "
3.	Mycobacterium avium-intracellulare Infection 02/01/1994 - "[Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, in Mycobacterium intracellulare infection induced in mice]." 12/01/1993 - "[Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, combined with a immunopotentiator, LC9018, in Mycobacterium intracellulare infection induced in beige mice]." 02/01/1996 - "The in vivo activities of KRM-1648 alone or in combination with both ethambutol (EB) and kanamycin (KM) or clarithromycin (CAM) were tested against Mycobacterium intracellulare infections in beige mice. " 02/01/1996 - "Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice."
4.	Acquired Immunodeficiency Syndrome (AIDS) 08/01/1994 - "KRM 1648 is a 4-aminobenzoxazine derivative of rifamycin S with potent in vitro activity against the Mycobacterium avium complex (MAC); the MIC for 90% of 24 MAC isolates from AIDS patients was 0.25 microgram/ml as determined by a radiometric broth macrodilution assay. " 02/01/1992 - "This may imply some difficulty with chemotherapy for AIDS-associated MAC infection, even with KRM-1648 treatment, which has excellent in vitro and in vivo anti-MAC activities, as shown in present study." 02/01/1992 - "When the MICs were determined by the agar dilution method with Middlebrook 7H11 agar medium, KRM-1648 exhibited similarly potent in vitro antimicrobial activities against the MAC isolated from AIDS and non-AIDS patients, indicating possible usefulness of KRM-1648 against AIDS-associated MAC infections. " 09/01/1998 - "Rifalazil is a rifamycin derivative from Kaneka that is in phase II clinical trials for the treatment of Mycobacterium tuberculosis (M tuberculosis; TB) and AIDS-associated Mycobacterium avium complex (MAC) infections [108254, 165543]. " 04/01/1993 - "avium complex infections in AIDS patients, was used to evaluate the therapeutic efficacy of KRM-1648, a newly synthesized benzoxazinorifamycin. "
5.	Peripheral Arterial Disease 01/27/2009 - "The objective of this phase-III trial was to assess the effect of a potent anti-Chlamydial agent, rifalazil, on peak walking time in patients with symptomatic peripheral artery disease. " 10/01/2007 - "A pivotal clinical trial with rifalazil has been initiated for the treatment of peripheral arterial disease. " 06/01/2006 - "A pivotal clinical trial with rifalazil has been initiated for the treatment of peripheral arterial disease. " 01/27/2009 - "No benefit of rifalazil therapy was found in the primary or any secondary end point among this cohort of patients with peripheral artery disease. " 01/27/2009 - "Patients with intermittent claudication secondary to peripheral artery disease who were seropositive for C pneumoniae were randomized to 25 mg rifalazil once weekly for 8 weeks or matching placebo. "

Related Drugs and Biologics

1.	KRM 1648
2.	Rifampin (Rifampicin)
3.	Rifabutin (Ansamycin)
4.	Anti-Bacterial Agents (Antibiotics)
5.	Isoniazid (Ftivazide)
6.	Ethambutol (Myambutol)
7.	mao-bushi-saishin-to
8.	Cytokines
9.	yokuinin
10.	Dihydrotachysterol (AT 10)

Related Therapies and Procedures

1.	Chinese Traditional Medicine (Traditional Chinese Medicine)
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)
4.	Aftercare (After-Treatment)